283 related articles for article (PubMed ID: 27756894)
21. Skeletal muscle miR-34a/SIRT1:AMPK axis is activated in experimental and human non-alcoholic steatohepatitis.
Simão AL; Afonso MB; Rodrigues PM; Gama-Carvalho M; Machado MV; Cortez-Pinto H; Rodrigues CMP; Castro RE
J Mol Med (Berl); 2019 Aug; 97(8):1113-1126. PubMed ID: 31139863
[TBL] [Abstract][Full Text] [Related]
22. Long noncoding RNA CCAT1 inhibits miR-613 to promote nonalcoholic fatty liver disease via increasing LXRα transcription.
Huang F; Liu H; Lei Z; Li Z; Zhang T; Yang M; Zhou K; Sun C
J Cell Physiol; 2020 Dec; 235(12):9819-9833. PubMed ID: 32413192
[TBL] [Abstract][Full Text] [Related]
23. miR-212 downregulation contributes to the protective effect of exercise against non-alcoholic fatty liver via targeting FGF-21.
Xiao J; Bei Y; Liu J; Dimitrova-Shumkovska J; Kuang D; Zhou Q; Li J; Yang Y; Xiang Y; Wang F; Yang C; Yang W
J Cell Mol Med; 2016 Feb; 20(2):204-16. PubMed ID: 26648452
[TBL] [Abstract][Full Text] [Related]
24. Ameliorative effects of bilirubin on cell culture model of non-alcoholic fatty liver disease.
Vakili O; Borji M; Saffari-Chaleshtori J; Shafiee SM
Mol Biol Rep; 2023 May; 50(5):4411-4422. PubMed ID: 36971910
[TBL] [Abstract][Full Text] [Related]
25. SIRT1 mediates the role of RNA-binding protein QKI 5 in the synthesis of triglycerides in non-alcoholic fatty liver disease mice via the PPARα/FoxO1 signaling pathway.
Zhang W; Sun Y; Liu W; Dong J; Chen J
Int J Mol Med; 2019 Mar; 43(3):1271-1280. PubMed ID: 30664220
[TBL] [Abstract][Full Text] [Related]
26. A micro-RNA expression signature for human NAFLD progression.
Guo Y; Xiong Y; Sheng Q; Zhao S; Wattacheril J; Flynn CR
J Gastroenterol; 2016 Oct; 51(10):1022-30. PubMed ID: 26874844
[TBL] [Abstract][Full Text] [Related]
27. miR-873-5p targets mitochondrial GNMT-Complex II interface contributing to non-alcoholic fatty liver disease.
Fernández-Tussy P; Fernández-Ramos D; Lopitz-Otsoa F; Simón J; Barbier-Torres L; Gomez-Santos B; Nuñez-Garcia M; Azkargorta M; Gutiérrez-de Juan V; Serrano-Macia M; Rodríguez-Agudo R; Iruzubieta P; Anguita J; Castro RE; Champagne D; Rincón M; Elortza F; Arslanow A; Krawczyk M; Lammert F; Kirchmeyer M; Behrmann I; Crespo J; Lu SC; Mato JM; Varela-Rey M; Aspichueta P; Delgado TC; Martínez-Chantar ML
Mol Metab; 2019 Nov; 29():40-54. PubMed ID: 31668391
[TBL] [Abstract][Full Text] [Related]
28. miR-222 targets ACOX1, promotes triglyceride accumulation in hepatocytes.
Wang JJ; Zhang YT; Tseng YJ; Zhang J
Hepatobiliary Pancreat Dis Int; 2019 Aug; 18(4):360-365. PubMed ID: 31126802
[TBL] [Abstract][Full Text] [Related]
29. Adipocytes-derived exosomal miR-122 promotes non-alcoholic fat liver disease progression via targeting Sirt1.
Chen K; Lin T; Yao W; Chen X; Xiong X; Huang Z
Gastroenterol Hepatol; 2023; 46(7):531-541. PubMed ID: 36584755
[TBL] [Abstract][Full Text] [Related]
30. Obesity-induced upregulation of miR-361-5p promotes hepatosteatosis through targeting Sirt1.
Zhang Z; Liu X; Xu H; Feng X; Lin Y; Huang Y; Peng Y; Gu M
Metabolism; 2018 Nov; 88():31-39. PubMed ID: 30309516
[TBL] [Abstract][Full Text] [Related]
31. Long noncoding RNA FLRL2 alleviated nonalcoholic fatty liver disease through Arntl-Sirt1 pathway.
Chen Y; Chen X; Gao J; Xu C; Xu P; Li Y; Zhu Y; Yu C
FASEB J; 2019 Oct; 33(10):11411-11419. PubMed ID: 31311301
[TBL] [Abstract][Full Text] [Related]
32. Pathogenesis of non-alcoholic fatty liver disease mediated by YAP.
Chen P; Luo Q; Huang C; Gao Q; Li L; Chen J; Chen B; Liu W; Zeng W; Chen Z
Hepatol Int; 2018 Jan; 12(1):26-36. PubMed ID: 29330836
[TBL] [Abstract][Full Text] [Related]
33. MiR-150 deficiency ameliorated hepatosteatosis and insulin resistance in nonalcoholic fatty liver disease via targeting CASP8 and FADD-like apoptosis regulator.
Zhuge B; Li G
Biochem Biophys Res Commun; 2017 Dec; 494(3-4):687-692. PubMed ID: 29107687
[TBL] [Abstract][Full Text] [Related]
34. LncRNA NEAT1 promotes hepatic lipid accumulation via regulating miR-146a-5p/ROCK1 in nonalcoholic fatty liver disease.
Chen X; Tan XR; Li SJ; Zhang XX
Life Sci; 2019 Oct; 235():116829. PubMed ID: 31484042
[TBL] [Abstract][Full Text] [Related]
35. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis.
Pirola CJ; Fernández Gianotti T; Castaño GO; Mallardi P; San Martino J; Mora Gonzalez Lopez Ledesma M; Flichman D; Mirshahi F; Sanyal AJ; Sookoian S
Gut; 2015 May; 64(5):800-12. PubMed ID: 24973316
[TBL] [Abstract][Full Text] [Related]
36. Downregulation of miR-192 causes hepatic steatosis and lipid accumulation by inducing SREBF1: Novel mechanism for bisphenol A-triggered non-alcoholic fatty liver disease.
Lin Y; Ding D; Huang Q; Liu Q; Lu H; Lu Y; Chi Y; Sun X; Ye G; Zhu H; Wei J; Dong S
Biochim Biophys Acta Mol Cell Biol Lipids; 2017 Sep; 1862(9):869-882. PubMed ID: 28483554
[TBL] [Abstract][Full Text] [Related]
37. MicroRNA expression analysis in high fat diet-induced NAFLD-NASH-HCC progression: study on C57BL/6J mice.
Tessitore A; Cicciarelli G; Del Vecchio F; Gaggiano A; Verzella D; Fischietti M; Mastroiaco V; Vetuschi A; Sferra R; Barnabei R; Capece D; Zazzeroni F; Alesse E
BMC Cancer; 2016 Jan; 16():3. PubMed ID: 26728044
[TBL] [Abstract][Full Text] [Related]
38. MiR-103-3p promotes hepatic steatosis to aggravate nonalcoholic fatty liver disease by targeting of ACOX1.
Ding J; Xia C; Cen P; Li S; Yu L; Zhu J; Jin J
Mol Biol Rep; 2022 Aug; 49(8):7297-7305. PubMed ID: 35606603
[TBL] [Abstract][Full Text] [Related]
39. Comparison of Gene Expression Patterns Between Mouse Models of Nonalcoholic Fatty Liver Disease and Liver Tissues From Patients.
Teufel A; Itzel T; Erhart W; Brosch M; Wang XY; Kim YO; von Schönfels W; Herrmann A; Brückner S; Stickel F; Dufour JF; Chavakis T; Hellerbrand C; Spang R; Maass T; Becker T; Schreiber S; Schafmayer C; Schuppan D; Hampe J
Gastroenterology; 2016 Sep; 151(3):513-525.e0. PubMed ID: 27318147
[TBL] [Abstract][Full Text] [Related]
40. MiR-149 Compromises the Reactions of Liver Cells to Fatty Acid via its Polymorphism and Increases Non-Alcoholic Fatty Liver Disease (NAFLD) Risk by Targeting Methylene Tetrahydrofolate Reductase (MTHFR).
An X; Yang Z; An Z
Med Sci Monit; 2017 May; 23():2299-2307. PubMed ID: 28507283
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
